CoChat

Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer

Open access
Segal, Neil H., Cercek, Andrea, Ku, Geoffrey, Wu, Abraham J., Rimner, Andreas, Khalil, Danny N., Reidy-Lagunes, Diane, Cuaron, John, Yang, T. Jonathan, Weiser, Martin R., Romesser, Paul B., Stadler, Zsofia K., Varghese, Anna M., Ganesh, Karuna, Yaeger, Rona, Connell, Louise C., Faleck, David, Abou-Alfa, Ghassan K., Mcauliffe, Kathleen C., Vaiskauskas, Pamela, Solter, Mark L., Ogle, Martinique, Adamow, Matthew J., Holland, Aliya, Vedantam, Pallavi, Wong, Phillip, Merghoub, Taha, Vakiani, Efsevia, Hollmann, Travis J., Juluru, Krishna, Chou, Joanne F., Capanu, Marinela, Erinjeri, Joseph, Solomon, Stephen, Yamada, Yoshiya, Kemeny, Nancy, Crane, Christopher H., Saltz, Leonard B. · 2021 · Clinical Cancer Research
Cited by 84

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Purpose: Immune checkpoint inhibition (ICI) alone is not active in mismatch repair–proficient (MMR-P) metastatic colorectal cancer (mCRC), nor does radiotherapy alone result in objective systemic benefit. However, combined radiotherapy plus ICI can induce systemic antitumor immunity in preclinical and clinical models. Patients and Methods: In this single-center, phase II study, patients with chemotherapy-refractory MMR-P mCRC received durvalumab 1,500 mg plus tremelimumab 75 mg every 4 weeks plus radiotherapy. The primary endpoint was objective response rate (ORR) in nonirradiated lesions. Treatment and efficacy were correlated with peripheral immune cell profiles. Results: We enrolled 24 patients, and report outcomes after a median follow-up of 21.8 (range: 15.9–26.3) months. The ORR was 8.3% (2 patients) [95% confidence interval (CI), 1.0–27.0]. The median progression-free survival was 1.8 (95% CI, 1.7–1.9) months, median overall survival was 11.4 (95% CI, 10.1–17.4) months. Twenty five percent of patients (n = 6) had treatment-related grade 3–4 adverse events. We observed increased circulating CD8+ T lymphocyte activation, differentiation, and proliferation in patients with objective response. Conclusions: This combination of radiotherapy plus ICI study did not meet the prespecified endpoint criteria to be considered worthwhile for further study. However, rare instances of systemic immune augmentation and regression in nonirradiated lesions were observed (an abscopal response). Combination durvalumab and tremelimumab plus radiotherapy is feasible in MMR-P mCRC with a manageable safety profile. Further studies of novel immunotherapy combinations, and identification of biomarkers predictive of abscopal response are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-2474

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 84

Metadata

Authors
Segal, N. H., Cercek, A., Ku, G., Wu, A. J., Rimner, A., Khalil, D. N., Reidy-Lagunes, D., Cuaron, J., Yang, T. J., Weiser, M. R., Romesser, P. B., Stadler, Z. K., Varghese, A. M., Ganesh, K., Yaeger, R., Connell, L. C., Faleck, D., Abou-Alfa, G. K., Mcauliffe, K. C., Vaiskauskas, P., Solter, M. L., Ogle, M., Adamow, M. J., Holland, A., Vedantam, P., Wong, P., Merghoub, T., Vakiani, E., Hollmann, T. J., Juluru, K., Chou, J. F., Capanu, M., Erinjeri, J., Solomon, S., Yamada, Y., Kemeny, N., Crane, C. H., & Saltz, L. B.
Venue
Clinical Cancer Research
Published
2021-01-27
Volume
27
Issue
8
Pages
2200-2208
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3125474097
Cited by
84
References
6
FWCI
5.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-2474
The paper
Segal, N. H., Cercek, A., Ku, G., Wu, A. J., Rimner, A., Khalil, D. N., Reidy-Lagunes, D., Cuaron, J., Yang, T. J., Weiser, M. R., Romesser, P. B., Stadler, Z. K., Varghese, A. M., Ganesh, K., Yaeger, R., Connell, L. C., Faleck, D., Abou-Alfa, G. K., Mcauliffe, K. C., . . . Saltz, L. B. (2021). Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-2474

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.